diclofenac has been researched along with Alzheimer Disease in 8 studies
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.
diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Efficacy measures comprised the Alzheimer's Disease Assessment Scale cognitive and noncognitive subsections, Global Deterioration Scale, Clinical Global Impression of Change, Mini-Mental State Examination, Instrumental Activities of Daily Living, Physical Self-Maintenance Scale, and a caregiver-rated Global Impression of Change." | 2.69 | A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. ( Christophidis, N; Mander, A; Scharf, S; Ugoni, A; Vajda, F, 1999) |
| "NSAIDs may prevent Alzheimer's disease (AD) but have failed as a treatment, possibly because only 1-2% of an oral NSAID dose reaches the brain." | 2.61 | Transspinal delivery of drugs by transdermal patch back-of-neck for Alzheimer's disease: a new route of administration. ( Lehrer, S; Rheinstein, PH, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stock, N | 1 |
| Munoz, B | 1 |
| Wrigley, JD | 1 |
| Shearman, MS | 1 |
| Beher, D | 1 |
| Peachey, J | 1 |
| Williamson, TL | 1 |
| Bain, G | 1 |
| Chen, W | 1 |
| Jiang, X | 1 |
| St-Jacques, R | 1 |
| Prasit, P | 1 |
| AlFadly, ED | 1 |
| Elzahhar, PA | 1 |
| Tramarin, A | 1 |
| Elkazaz, S | 1 |
| Shaltout, H | 1 |
| Abu-Serie, MM | 1 |
| Janockova, J | 1 |
| Soukup, O | 1 |
| Ghareeb, DA | 1 |
| El-Yazbi, AF | 1 |
| Rafeh, RW | 1 |
| Bakkar, NZ | 1 |
| Kobeissy, F | 1 |
| Iriepa, I | 1 |
| Moraleda, I | 1 |
| Saudi, MNS | 1 |
| Bartolini, M | 1 |
| Belal, ASF | 1 |
| Sagar, SR | 1 |
| Singh, DP | 1 |
| Das, RD | 1 |
| Panchal, NB | 1 |
| Sudarsanam, V | 1 |
| Nivsarkar, M | 1 |
| Vasu, KK | 1 |
| Li, X | 1 |
| Li, J | 2 |
| Huang, Y | 1 |
| Gong, Q | 1 |
| Fu, Y | 1 |
| Xu, Y | 1 |
| Huang, J | 1 |
| You, H | 1 |
| Zhang, D | 2 |
| Mao, F | 1 |
| Zhu, J | 1 |
| Wang, H | 1 |
| Zhang, H | 1 |
| Lehrer, S | 1 |
| Rheinstein, PH | 1 |
| Cohen, MP | 1 |
| Shearman, CW | 1 |
| Lacomblez, L | 1 |
| Scharf, S | 1 |
| Mander, A | 1 |
| Ugoni, A | 1 |
| Vajda, F | 1 |
| Christophidis, N | 1 |
1 review available for diclofenac and Alzheimer Disease
| Article | Year |
|---|---|
Transspinal delivery of drugs by transdermal patch back-of-neck for Alzheimer's disease: a new route of administration.
Topics: Administration, Cutaneous; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Antineoplasti | 2019 |
1 trial available for diclofenac and Alzheimer Disease
| Article | Year |
|---|---|
A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Cognition; Dicl | 1999 |
6 other studies available for diclofenac and Alzheimer Disease
| Article | Year |
|---|---|
The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, N | 2006 |
Tackling neuroinflammation and cholinergic deficit in Alzheimer's disease: Multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenase.
Topics: Acetylcholine; Alzheimer Disease; Animals; Cell Line; Cholinesterase Inhibitors; Cyclooxygenase 2 In | 2019 |
Investigations on substituted (2-aminothiazol-5-yl)(imidazo[1,2-a]pyridin-3-yl)methanones for the treatment of Alzheimer's disease.
Topics: Aluminum Chloride; Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dose-Respons | 2021 |
The novel therapeutic strategy of vilazodone-donepezil chimeras as potent triple-target ligands for the potential treatment of Alzheimer's disease with comorbid depression.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antidepressive Agents; Binding Sites; Brain; Choli | 2022 |
Reduction of Abeta42 in brains of transgenic APPswe mice by 2-3-chlorophenylaminophenylacetate.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Diclofenac | 2009 |
[Inflammation, nonsteroidal anti-inflammatory drugs and Alzheimer disease].
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Cyclooxy | 2004 |